![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Oncol. , 25 September 2020
Sec. Cancer Molecular Targets and Therapeutics
Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.591112
This article is a correction to:
The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma
A Corrigendum on
The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma
by Cheng, F., Zhang, P., Xiao, Q., Li, Y., Dong, M., Wang, H., et al. (2019). Front. Oncol. 9:447. doi: 10.3389/fonc.2019.00447
In the original article, there was a mistake in Figure 4 as published. The second and third image in the first row of Figure 4A are the same. The corrected Figure 4 appears below.
Figure 4. LRIG3 and sLRIG3 inhibit migration and invasion of glioma cells. (A) Wound-healing assay of GL15, U87, and PriGBM cells overexpressing full-length LRIG3 and LRIG3 ectodomain proteins (sLRIG3). Representative images of wounded cell monolayers. Scale bar, 100 μm. (B) Quantification of healing areas of the different groups from each cell lines (Data represent the mean ± SD of triplicates from healing areas of one experiment. *p < 0.05; **p < 0.01 vs. control group; one-way ANOVA). (C) Invasion capacity as measured by transwell invasion assays. Representative images of the microscopic fields are shown. Scale bar, 50 μm. (D) Numbers of migrated cells per microscopic field were analyzed from five predetermined fields (Data represent the mean ± SD. *p < 0.05; **p < 0.01 vs. control group; one-way ANOVA).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: glioma, glioblastoma, LRIG3, soluble LRIG3, MET/PI3K/Akt pathway, prognosis
Citation: Cheng F, Zhang P, Xiao Q, Li Y, Dong M, Wang H, Kuang D, He Y, Duan Q, Mao F, Wang B and Guo D (2020) Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma. Front. Oncol. 10:591112. doi: 10.3389/fonc.2020.591112
Received: 04 August 2020; Accepted: 14 August 2020;
Published: 25 September 2020.
Edited and reviewed by: Thomas Daubon, UMR5095 Institut de Biochimie et Génétique Cellulaires (IBGC), France
Copyright © 2020 Cheng, Zhang, Xiao, Li, Dong, Wang, Kuang, He, Duan, Mao, Wang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Baofeng Wang, d2JmNjIwQDE2My5jb20=; Dongsheng Guo, Z3VvZG9uZ3NoZW5nQHlhaG9vLmNvbQ==
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.